Cediranib, Paclitaxel, and Carboplatin in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Lung Cancer Clinical Trial

Official title:

A Double Blind Randomized Trial of Cediranib Versus Placebo in Patients Receiving Paclitaxel/Carboplatin Chemotherapy for the Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00795340
• Other study ID #: BR29
• Secondary ID: CAN-NCIC-BR29CDR
• Status: Completed
• Phase: Phase 3
• Start date: February 4, 2009
• Est. completion date: January 16, 2014

Study information

• Verified date: June 2015
• Source: Canadian Cancer Trials Group
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

RATIONALE: Cediranib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known whether cediranib is more effective than a placebo when given together with paclitaxel and carboplatin in treating patients with non-small cell lung cancer.

PURPOSE: This randomized phase III trial is studying how well cediranib works when given together with paclitaxel and carboplatin in treating patients with stage IIIB or stage IV non-small cell lung cancer.

Description:

OBJECTIVES:

Primary

• To compare overall survival of patients with stage IIIB-IV non-small cell lung cancer treated with cediranib vs placebo administered in combination with paclitaxel and carboplatin.

Secondary

• To compare the progression-free survival of patients treated with these regimens.

• To compare the objective response rates in patients treated with these regimens.

• To estimate time to response and response duration in patients treated with these regimens.

• To evaluate the nature, severity, and frequency of toxicities, including hemorrhage and hemoptysis, in patients treated with these regimens.

• To compare the pharmacokinetics of paclitaxel between the two arms in a subset of enrolled patients

• To compare the quality of life of patients treated with these regimens.

• To determine the incremental cost effectiveness and cost utility ratios for these regimens.

• To correlate the expression of tissue markers (at diagnosis) with outcomes and response in an exploratory fashion OUTLINE: This is a multicenter study. Patients are stratified by gender, center, disease stage (IIIB vs IV), weight loss (< 5% vs 5-10% vs unknown), and prior adjuvant chemotherapy (yes vs no). Patients are randomized to 1 of 2 treatment arms.

• Arm I: Patients receive oral cediranib once daily on days 1-21 and paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1.

• Arm II: Patients receive oral placebo once daily on days 1-21 and paclitaxel and carboplatin as in arm I.

Treatment in both arms repeats every 21 days for 4 to 6 courses in the absence of disease progression or unacceptable toxicity.

Quality of life is assessed at baseline, on day 1 of each course, and periodically thereafter.

After completion of study therapy, patients are followed every 12 weeks.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 306
• Est. completion date: January 16, 2014
• Est. primary completion date: January 9, 2012
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

DISEASE CHARACTERISTICS:

• Histologically or cytologically* confirmed non-small cell carcinoma of the lung

• Stage IIIB or IV disease NOTE: *Diagnosis by sputum cytology alone allowed provided it is confirmed by a second sputum specimen

• Measurable disease, defined as at least 1 measurable lesion > 20 mm by x-ray, ultrasound, or physical exam or = 10 mm (lymph nodes must be = 15 mm in the short axis) by spiral CT scan or physical exam (in the first 260 patients randomized**)

• Measurable lesions that are sole sites of disease must be outside a previous radiotherapy field unless disease progression has been documented NOTE: **Measurable or nonmeasurable disease allowed after the first 260 patients

• No appreciable cavitation in central thoracic lesions

• No untreated brain or meningeal metastases

• Patients with treated and radiologic or clinical evidence of stable brain metastases, with no evidence of cavitation or hemorrhage in the brain lesion, are eligible provided the metastases are asymptomatic and do not require corticosteroids

• No pleural effusion

PATIENT CHARACTERISTICS:

• ECOG performance status 0-1

• Absolute granulocyte count = 1,500/mm^3

• Platelet count = 100,000/mm^3

• Creatinine clearance > 50 mL/min

• Total bilirubin = 1.5 times upper limit of normal (ULN)

• ALT = 2 times ULN (< 5 times ULN if due to liver metastasis)

• Not pregnant or nursing

• Negative pregnancy test

• Fertile patients must use effective double-method contraception (barrier method for men)

• No other malignancy within the past 5 years, except in situ cancer, basal cell or squamous cell skin cancer, or malignancy cured by definitive prior therapy alone (e.g., surgery) and continuously disease-free for at least 5 years

• Mean QTc with Bazett correction = 480 msec in screening ECG (at least one value must be = 480 msec when measured automatically or manually corrected using Bazett's or Fridericia's correction)

• No history of familial long QT syndrome

• No untreated and/or uncontrolled cardiovascular conditions and/or symptomatic cardiac dysfunction including any of the following:

• Unstable angina

• Congestive heart failure

• Myocardial infarction within the past year

• Cardiac ventricular arrhythmias requiring medication

• History of second or third degree atrioventricular conduction defects

• LVEF > 50% in patients with significant cardiac history, even if controlled

• No resting BP consistently > 150 mm Hg systolic and/or > 100 mm Hg diastolic

• No poorly controlled hypertension

• No history of labile hypertension or poor compliance with anti-hypertensive medication

• No overt bleeding (> 30 mL bleeding/episode) from any site within the past 3 months

• No clinically relevant hemoptysis (> 5 mL fresh blood) within the past 4 weeks

• Flecks of blood in sputum allowed

• No active or uncontrolled infections, or serious illnesses or medical conditions which would not permit the patient to be treated according to the study

• No prior allergic reactions to drugs containing Cremophor EL®

• No inflammatory bowel disease (e.g., Crohn disease or ulcerative colitis)

• No documented weight loss > 10% within the past 3 months

• Patients with weight loss 5-10% or whose weight loss status is unknown are eligible provided serum albumin levels are = 30 g/L

• No peripheral neuropathy > grade 1

• Must be fit for combined modality treatment

• Sufficiently fluent and willing to complete quality-of-life questionnaires

PRIOR CONCURRENT THERAPY:

• See Disease Characteristics

• Recovered from all prior therapy

• No prior chemotherapy for metastatic or recurrent disease

• No prior anti-angiogenic therapy (e.g., bevacizumab, cediranib, AZD6474, PTK/ZK, sunitinib malate, or other agents considered angiogenesis inhibitors by NCIC Clinical Trials Group for any indication)

• Prior cox-2 inhibitors in standard doses allowed

• At least 12 months since prior adjuvant chemotherapy for completely resected disease

• Combined chemotherapy/radiotherapy regimens for locally advanced stage IIIB disease not allowed

• At least 21 days since prior radiotherapy

• At least 21 days since prior cetuximab or other monoclonal antibodies

• At least 14 days since prior EGFR inhibitor therapy for adjuvant therapy or metastatic disease (e.g., tyrosine kinase inhibitors, vaccines, or other agents considered by NCIC CTG as acting on the EGFR pathway)

• At least 14 days since prior major surgery

• At least 1 week since prior corticosteroids

• No other concurrent experimental drugs, anticancer treatment, or investigational therapy

Related Conditions & MeSH terms

• Carcinoma, Non-Small-Cell Lung
• Lung Cancer
• Lung Neoplasms

Intervention

Drug:
• carboplatin
Given IV
• cediranib maleate
Given orally
• paclitaxel
Given IV

Other:
• placebo
Given orally

Locations

Country	Name	City	State
Brazil	Instituto Nacional de Cancer (INCA)	Rio de Janeiro
Brazil	Instituto de Cancer Arnaldo Vieira de Carvalho	Sao Paulo
Canada	BCCA - Abbotsford Centre	Abbotsford	British Columbia
Canada	Tom Baker Cancer Centre	Calgary	Alberta
Canada	Cross Cancer Institute	Edmonton	Alberta
Canada	Juravinski Cancer Centre at Hamilton Health Sciences	Hamilton	Ontario
Canada	Cancer Centre of Southeastern Ontario at Kingston	Kingston	Ontario
Canada	London Regional Cancer Program	London	Ontario
Canada	McGill University - Dept. Oncology	Montreal	Quebec
Canada	Ottawa Health Research Institute - General Division	Ottawa	Ontario
Canada	University Institute of Cardiology and	Quebec
Canada	Allan Blair Cancer Centre	Regina	Saskatchewan
Canada	Algoma District Cancer Program	Sault Ste. Marie	Ontario
Canada	Niagara Health System	St. Catharines	Ontario
Canada	BCCA - Fraser Valley Cancer Centre	Surrey	British Columbia
Canada	Mount Sinai Hospital	Toronto	Ontario
Canada	Univ. Health Network-Princess Margaret Hospital	Toronto	Ontario
Canada	BCCA - Vancouver Cancer Centre	Vancouver	British Columbia
Canada	Windsor Regional Cancer Centre	Windsor	Ontario

Sponsors (1)

Lead Sponsor	Collaborator
NCIC Clinical Trials Group

Countries where clinical trial is conducted

Brazil,  Canada, 

References & Publications (1)

Laurie SA, Solomon BJ, Seymour L, Ellis PM, Goss GD, Shepherd FA, Boyer MJ, Arnold AM, Clingan P, Laberge F, Fenton D, Hirsh V, Zukin M, Stockler MR, Lee CW, Chen EX, Montenegro A, Ding K, Bradbury PA. Randomised, double-blind trial of carboplatin and pac — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Overall Survival	Medians of survival time, and their confidence intervals.	at every 3 months visit throughout trial, a median of 13.1 months.
Secondary	Progression-free Survival	Medians of PFS and their confidence intervals by arm	at every 3 months visit throughout trial, a median of 12 months
Secondary	Objective Tumor Response as Assessed by RECIST Criteria v1.1.	Every 6 weeks at the end of every 2 cycles during protocol treatment and every 12 weeks after protocol treatment until progression.	Every 6 weeks at the end of every 2 cycles during protocol treatment and every 12 weeks after protocol treatment until progression.